Professional Summary
Professional Overview
Susan Sobolov is an accomplished life sciences executive with over 15 years of experience leading cross-functional teams and driving strategic initiatives in the biotech and pharmaceutical industries. As the President of RIGImmune Inc., she is responsible for overseeing the company's overall operations, R&D strategy, and business development efforts, with a focus on advancing innovative immunotherapy solutions.
Experience Summary
Current Role
As the President of RIGImmune Inc., Susan is responsible for setting the strategic direction of the company and ensuring the successful execution of its pipeline of novel immunotherapies. She leads a team of experienced researchers, clinicians, and business professionals in the development and commercialization of innovative treatments for autoimmune and oncological disorders. Under her leadership, RIGImmune has secured multiple strategic partnerships and made significant advancements in its clinical trial programs.
Career Progression
Prior to joining RIGImmune, Susan served as the Chief Operating Officer at Caelum Biosciences, where she spearheaded the company's corporate and operational strategy, including the successful completion of a $30 million Series B financing round. She has also held various leadership roles at Fortress Biotech, Alexion Pharmaceuticals, and Vertex Pharmaceuticals, where she demonstrated her expertise in program management, global project leadership, and cross-functional collaboration.
Academic Background
Susan holds a Master of Business Administration (MBA) from the University of Pennsylvania's Wharton School and a Bachelor of Science (BS) in Biochemistry from the University of California, Los Angeles (UCLA).
Areas of Expertise
- Immunotherapy and autoimmune disease treatment
- Biopharmaceutical research and development
- Strategic planning and business development
- Project management and cross-functional team leadership
- Regulatory affairs and quality assurance
Professional Impact
Throughout her career, Susan has been instrumental in advancing the development of several groundbreaking therapies, including the successful regulatory approval and commercialization of a first-in-class complement inhibitor for the treatment of rare autoimmune disorders. She has also played a key role in securing multiple strategic partnerships and securing significant funding to support the continued growth and innovation of the companies she has served.
Conclusion
With her exceptional track record of leadership, strategic vision, and industry expertise, Susan Sobolov is well-positioned to drive RIGImmune's mission of developing innovative immunotherapies that address unmet medical needs and improve the lives of patients worldwide.
